Introduction
============

Preoperative 5-fluorouracil-based chemoradiotherapy (CRT) followed by mesorectal excision is the standard treatment for patients with locally advanced rectal cancer (LARC) ([@b1-ol-0-0-6141]--[@b3-ol-0-0-6141]). Several previous studies have demonstrated that CRT significantly downstages the disease and reduces the risk of local tumor recurrence ([@b4-ol-0-0-6141]--[@b6-ol-0-0-6141]). The response rate to CRT in this group varies, with 9--30% of patients having a pathological complete response (pCR) and 46--60% achieving some degree of tumor downstaging ([@b7-ol-0-0-6141],[@b8-ol-0-0-6141]). An improved long-term outcome has been demonstrated for patients with pCR compared with patients who are non-responsive to CRT ([@b9-ol-0-0-6141]--[@b12-ol-0-0-6141]); however, this treatment has several long-term side effects. Therefore, the appropriate selection of patients who will respond to CRT is important. At present, only certain clinical parameters and radiological investigations are available for use in the selection of patients for CRT, which is insufficient. There is a requirement for biomarkers that are able to predict the effect of preoperative CRT.

MicroRNAs (miRNAs/miRs) are short (18--25 nucleotides) non-coding RNA molecules that act as negative gene regulators at the post-transcriptional level. miRNAs serve an important role in the regulation of biological processes, such as cell differentiation, proliferation and apoptosis. Numerous miRNAs interfere with the expression of oncogenes and tumor suppressor genes with a direct involvement in carcinogenesis ([@b13-ol-0-0-6141],[@b14-ol-0-0-6141]). Due to their association with cancer, miRNAs are being investigated as potential diagnostic and prognostic biomarkers, and predictors of treatment response ([@b15-ol-0-0-6141],[@b16-ol-0-0-6141]).

In the present study, 5 miRNAs were chosen for study based on the literature and our group\'s previous methodological work. In rectal cancer tissue, reference genes (miR-193a-5p, miR −27a and let-7g) for the relative quantification of miRNAs have previously been identified ([@b17-ol-0-0-6141]) and the intratumoral heterogeneity of the present panel of miRNAs (miR-21, −31, −125b, −145 and −630) has been assessed ([@b18-ol-0-0-6141]).

miRNA-21 is overexpressed in rectal cancer and its downregulation following neoadjuvant CRT has been suggested ([@b19-ol-0-0-6141]--[@b21-ol-0-0-6141]). Furthermore, overexpression of miRNA-21 has been associated with complete tumor regression following neoadjuvant CRT ([@b22-ol-0-0-6141]). Increased expression of miRNA-31 has been detected in colorectal cancer (CRC), with a positive correlation between its expression and the stage of the disease ([@b23-ol-0-0-6141],[@b24-ol-0-0-6141]). In addition, the upregulation of miRNA-125b and miRNA-145 in rectal cancer tissue following neoadjuvant CRT has been reported ([@b19-ol-0-0-6141],[@b25-ol-0-0-6141]). Della Vittoria Scarpati *et al* ([@b26-ol-0-0-6141]) demonstrated that miRNA-630 had 100% sensitivity and specificity in selecting patients with complete tumor regression following CRT. However, only one of the studies described above included a validation of their results ([@b22-ol-0-0-6141]). Consequently, the majority of them serve as hypothesis-generating investigations. The present study aimed to analyze the association between miRNA expression and the treatment efficacy of preoperative CRT in a test cohort of LARC patients, and to subsequently validate the results in an independent cohort.

Materials and methods
=====================

### Patient populations

Reporting of all data in the present study is in accordance with the Reporting recommendations for tumor marker prognostic studies criteria ([@b27-ol-0-0-6141]). The present study consisted of a test and a validation cohort of patients with LARC. The patients were enrolled in previously conducted clinical trials, and the details of patients, treatment and follow-up interval times are available from the pertaining publications ([@b28-ol-0-0-6141]--[@b30-ol-0-0-6141]). Briefly, the test cohort began with 85 patients treated in one of two following trials: i) 50 patients (enrollment, November 2002-June 2004) with resectable T3 rectal cancer treated with preoperative CRT (60 Gy/30 fractions, and concurrent tegafur-uracil (300 mg/m^2^) and L-leucovorin (22.5 mg/day) combined with an endorectal boost (5 Gy/1 fraction) ([@b28-ol-0-0-6141]); ii) 35 patients (enrollment, June 2004-January 2005) with resectable T3-4 rectal cancer receiving similar treatment combined with the cyclooxygenase-2-inhibitor celecoxib (400 mg twice a day) ([@b30-ol-0-0-6141]). The validation cohort (enrollment, March 2005-November 2009) was based on a previous randomized phase III trial ([@b29-ol-0-0-6141]) of 224 patients with resectable T3-4 rectal cancer receiving neoadjuvant CRT (50.4 Gy/28 fractions, and concomitant tegafur-uracil (300 mg/m^2^) and L-leucovorin (22.5 mg/day) with (arm B) or without (arm A) an endorectal boost (10 Gy/2 fractions)).

The present study was approved by the Regional Committee on Health Research Ethics of Southern Denmark and the requirement for written informed consent was waived (protocol ID no. S-20140083). The study was registered with The Danish Data Protection Agency and The Danish Registry of Human Tissue Utilization was consulted prior to any tissue samples being used. The inclusion criteria were the availability of formalin-fixed paraffin-embedded (FFPE) diagnostic biopsies containing adenocarcinoma tissue and tumor specimens for the pathological evaluation of tumor regression grade (TRG). The exclusion criteria were the presence of synchronous malignant diseases (with the exception of non-melanoma skin cancer and carcinoma *in situ* of the cervical uterus). A total of 55 and 130 patients from the test and validation cohorts, respectively, met the criteria for the present investigation. Flowcharts of the study populations are presented in [Fig. 1](#f1-ol-0-0-6141){ref-type="fig"} and a summary of their clinicopathological characteristics are presented in [Table I](#tI-ol-0-0-6141){ref-type="table"}.

### Samples

Diagnostic biopsies from the rectal tumors followed routine preservation (FFPE), and were transported and stored at room temperature. The median storage duration from archiving to analysis was 11.5 years in the test cohort and 9 years in the validation cohort. Histological sections stained with hematoxylin and eosin (H&E) were examined by a pathologist in order to ensure the presence of tumor cells in the analyzed sections. From the corresponding tissue blocks, 8-µm-thick sections were cut for use in subsequent reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. In the test population, areas of tumor cells were identified by a pathologist and encircled as regions of interest (ROI) on an image of the H&E-stained section. The ROI were isolated through membrane-based laser microdissection (LMD) using a Leica LMD6500 Microsystems (Leica Microsystems GmbH, Wetzlar, Germany) and collected in the caps of 0.5 ml RNase-free PCR tubes with a drop of ethanol (99%). In the validation population, LMD was performed as described above. However, in a subset of cases in the validation cohort LMD was not required, since the whole biopsy consisted of tumor tissue without marked inflammation. In these cases (N=26) the tissue was removed from the slides using a scalpel and collected into 1.5 ml RNase-free PCR tubes containing a drop of ethanol (99%).

### Expression analysis via RT-qpcr

#### Normalizer miRNAs

Recently, our group performed a study ([@b17-ol-0-0-6141]) on miRNA expression profiling to identify and validate reference genes for the relative quantification of miRNAs in rectal cancer tissue. miR-193a-5p, miR-27a and let-7g were identified as the most stably expressed miRNAs in rectal cancer tissue, and the mean expression value of these three miRNAs were subsequently used for normalization in the present study.

#### RNA extraction

Total RNA was isolated from the FFPE tissue using the miRNeasy FFPE kit for the test study and the AllPrep DNA/RNA FFPE kit (both Qiagen GmbH, Hilden, Germany) for the validation study according to the manufacturer\'s protocol. Total RNA was eluted into 14 µl RNase-free water.

#### RT-qPCR

RT and preamplification were performed as previously described ([@b18-ol-0-0-6141]). Custom TaqMan^®^ MicroRNA Single Assays (Thermo Fisher Scientific, Inc., Waltham, MA, USA) for hsa-let-7g (cat. no. 002282), hsa-miR-193a-5p (cat. no. 002281), hsa-miR-27a (cat. no. 000408), hsa-miR-21 (cat. no. 000397), hsa-miR-31 (cat. no. 002279), hsa-miR-125b (cat. no. 000449), hsa-miR-145 (cat. no. 002278) and hsa-miR-630 (cat. no. 001563) were used, according to the manufacturer\'s protocol. The qPCR analyses were carried out using a QuantStudio™ 12K Flex Real-Time PCR system (Thermo Fisher Scientific, Inc.) with 1 µl diluted preamplification product, TaqMan MicroRNA Assays and TaqMan^®^ Universal Master Mix II NoAmpErase^®^ UNG in a total reaction volume of 20 µl. All reactions were performed in triplicate. Data analysis was performed using Quantstudio 12K Flex software (version 1.2.2; Thermo Fisher Scientific, Inc.) and relative quantification was performed using the 2^−ΔΔCq^ method as described by Eriksen *et al* ([@b18-ol-0-0-6141]). The mean expression value of miR-193a-5p, miR-27a and let-7g was used as the normalization factor. Water was used as the negative control. A no-template control was included in the entire process and analyzed together with samples. The analyses were performed by staff blinded to the patient outcome.

#### Endpoints

The primary endpoint of tumor regression was determined by assessing the operative specimens according to Mandard\'s Tumor Regression Grade (TRG) system ([@b31-ol-0-0-6141],[@b32-ol-0-0-6141]), as follows: TRG1, no residual tumor; TRG2, microscopic residual tumor; TRG3, moderate response; TRG4, minor response; and TRG5, no response. Overall survival (OS) and disease-free survival (DFS) were the secondary endpoints. OS was defined as the time from inclusion in the primary study until mortality from any cause. DFS was calculated as the time from inclusion in the primary study until the first documented tumor progression or mortality from any cause.

#### Statistical analysis

Wilcoxon rank-sum test was used for comparison of medians between groups. The prognostic value of variables was analyzed using the log rank-test and survival curves were produced using the Kaplan-Meier estimator. Patients with additional malignancies were excluded from the DFS analysis (test study, N=9; validation study, N=16). Clinical outcome data were last updated in April 2016. Possible correlations between continuous data were analyzed and visualized using the parametric linear regression analysis. Univariate Cox\'s regression analysis was used to estimate the prognostic value of individual variables and those with P\<0.1 were included in a multivariate Cox\'s regression analysis for independent prognostic value. All tests were two-tailed. All statistical analyses were performed using NCSS Statistical Software 2007 (version 07.1.20; NSCC, LLC, Kaysville, UT, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Test population

The test cohort analyses consisted of 55 patients and the treatment compliance was high ([@b28-ol-0-0-6141]). The median follow-up time was 11.6 years. All patients were responsive to preoperative CRT. Patient characteristics and treatment responses are presented in [Table I](#tI-ol-0-0-6141){ref-type="table"}. An expression of miR-145 below the median expression level was significantly associated with major response (TRG1+2) to treatment (P\<0.001; [Table II](#tII-ol-0-0-6141){ref-type="table"}). For the other investigated miRNAs no significant association between their expression and TRG was identified ([Table II](#tII-ol-0-0-6141){ref-type="table"}). For survival analysis, patients were grouped according to their median expression of the miRNA of interest \[above (high) or below (low) the median\]. No significant difference was identified between the high and low expression groups for the investigated miRNAs following OS and DFS analyses (data not shown).

### Validation population

A total of 130 patients were included in the validation population. Patient characteristics and treatment responses are presented in [Table I](#tI-ol-0-0-6141){ref-type="table"}. All patients, with the exception of two, received \>80% of the planned radiotherapy with a curative intent. Eight patients had developed distant metastases in the liver and/or lungs at the time of surgery. In the validation population, an expression of miR-21 above the median expression level was significantly associated (P=0.035) with major response (TRG1+2) to treatment ([Table III](#tIII-ol-0-0-6141){ref-type="table"}). The association between miR-145 expression and TRG was similar to the one demonstrated in the test cohort, although it did not reach statistical significance (P=0.085). For miR-125b, −31 and −630, no significant association between expression and TRG was detected ([Table III](#tIII-ol-0-0-6141){ref-type="table"}).

Grouping patients in the validation cohort according to their median expression of the miRNA of interest revealed that patients with miR-125b and miR-145 expression below the median had a significantly better DFS compared with those with expression above the median ([Table IV](#tIV-ol-0-0-6141){ref-type="table"}). Survival curves for miR-145 are illustrated in [Fig. 2](#f2-ol-0-0-6141){ref-type="fig"}. No significant difference in DFS was detected for miR-21, −31 and −630 ([Table IV](#tIV-ol-0-0-6141){ref-type="table"}). No significant difference was demonstrated between the high and low expression of any of the investigated miRNAs and OS ([Table IV](#tIV-ol-0-0-6141){ref-type="table"}).

For a parameter to be included in the multivariate Cox\'s regression analysis, a cut-off significance level of P\<0.1 in the univariate analysis was pre-specified. In the linear regression analysis, a significant positive correlation was demonstrated between miR-125b and miR-145 expression (r=0.73; P\<0.0001; [Fig. 3](#f3-ol-0-0-6141){ref-type="fig"}), and therefore they were included in a separate multivariate analysis ([Table V](#tV-ol-0-0-6141){ref-type="table"}). Resection status (P=0.002, [Table V](#tV-ol-0-0-6141){ref-type="table"}) and miR-125b expression (P=0.026, [Table V](#tV-ol-0-0-6141){ref-type="table"}) remained significant in predicting DFS, and a borderline significance was demonstrated for miR-145 expression (P=0.053). Multivariate analysis was not performed for OS, as none of the investigated miRNAs were significantly associated with OS in the univariate analysis.

Discussion
==========

The balance between treatment efficacy and toxicity is a major issue in the clinical management of patients with LARC. Identifying molecular biomarkers capable of predicting the response of patients to preoperative CRT is therefore important. The 'watchful waiting' strategy is emerging as an alternative the typical preoperative CRT followed by surgery; thus far, a number of studies have revealed encouraging outcomes for this strategy ([@b33-ol-0-0-6141]--[@b37-ol-0-0-6141]). If tumor response to neoadjuvant CRT could be predicted it would facilitate in providing more individualized treatment planning, whereby patients with pCR could avoid the standard resection procedure, which is frequently followed by a high risk of morbidity.

It has previously been demonstrated by Ryan *et al* ([@b38-ol-0-0-6141]) that patients with TRG1 and TRG2 tumors can be regarded as having pCR to preoperative CRT. In addition, Lindebjerg *et al* ([@b39-ol-0-0-6141]) demonstrated that 28% of tumors originally classified as TRG1 were reclassified as TRG2 tumors following step sectioning ([@b39-ol-0-0-6141]). Based on these results, patients with TRG1 and TRG2 were pooled as complete responders in the present study and compared with patients with a poorer response (TRG3+4).

In the present study, the expression of selected miRNAs in diagnostic biopsies from patients with locally advanced T3-4 rectal cancer was analyzed. The results demonstrated a significant association between miR-145 expression and the overall response of patients with rectal cancer to preoperative CRT. Furthermore, the results suggest a possible association between miR-21 and TRG, and between miR-125b and DFS.

In the test cohort, a significant association between low miR-145 expression and major treatment response (TRG1+2) was detected. Similarly, this association was identified in the validation cohort; however, it did not reach statistical significance (P=0.085). Drebber *et al* ([@b19-ol-0-0-6141]) reported a significant correlation between a major response to neoadjuvant CRT and a high level of miR-145 expression. However, the results of this study are difficult to compare with those of the present study, since they used a different tumor regression grading system ([@b40-ol-0-0-6141]) and performed macrodissection, whereas the majority of the samples in the current study underwent laser microdissection.

The significant association between a high expression of miR-21 and TRG1+2 in the validation population is in accordance with a previous study by Lopes-Ramos *et al* ([@b22-ol-0-0-6141]), which revealed that the overexpression of miR-21-5p is predictive of complete tumor regression following neoadjuvant CRT in patients with rectal cancer with a sensitivity and specificity of 78 and 86%, respectively. Furthermore, Bandres *et al* ([@b41-ol-0-0-6141]) revealed that an upregulation of miR-21 was associated with TRG1 or TRG2 tumors. The results of the test study population in the present study did not identify the same association between miR-21 expression and treatment response. Results from the test cohort suggested an association between a low expression of miR-21 and a major treatment response, but this did not reach statistical significance. However, in the validation population there was a significant association between a high miR-21 expression and a major response to preoperative CRT, in agreement with Lopes-Ramos *et al* ([@b22-ol-0-0-6141]) and Bandres *et al* ([@b41-ol-0-0-6141]).

miR-125b and miR-31 were included in the present study based on previous literature on miRNAs associated with rectal cancer ([@b23-ol-0-0-6141]--[@b25-ol-0-0-6141]). In the current study, no association between their expression and response to preoperative CRT was detected. However, the significant association between a low expression of miR-125b and increased DFS in the validation cohort requires further investigation.

The results from a study by Della Vittoria Scarpati *et al* ([@b26-ol-0-0-6141]), which demonstrated that miR-630 had 100% sensitivity and specificity in selecting patients having pCR after undergoing CRT (N=38), were not confirmed in the current study. The expression of miR-630 was analyzed in diagnostic biopsies from a total of 185 patients in the present study. In general, miR-630 was sparsely expressed, and it was undetected in 24 samples. Previously, high intratumoral heterogeneity has been reported regarding miR-630 expression in rectal cancer ([@b18-ol-0-0-6141]).

In conclusion, the partially diverging results between the test and the validation cohorts in the present study underline the importance of the validation of biomarker studies. This issue has not been adequately addressed in the previous literature. The majority of studies include \<50 patients with no validation. The risk of positive results being considered false positives in investigations with small cohorts is high. This approach has hampered or delayed the clinical application of diagnostic and prognostic biomarkers. The results of the present study underline the necessity for large prospective trials of miRNA biomarkers in the future.
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###### 

Clinicopathological characteristics and response to chemoradiotherapy of patients in the test and validation study cohorts.

  Clinicopathological characteristic   Test cohort (N=55), no. of patients (%)   Validation cohort (N=130), no. of patients (%)
  ------------------------------------ ----------------------------------------- ------------------------------------------------
  Gender                                                                         
    Female                             19 (34.5)                                 50 (38)
    Male                               36 (65.5)                                 80 (62)
  T-stage                                                                        
    T3                                 48 (87)                                   110 (85)
    T4                                 7 (13)                                    20 (15)
  N-stage                                                                        
    N0                                 16 (29)                                   14 (11)
    N^+^                               39 (71)                                   116 (89)
  TRG                                                                            
    TRG1                               13 (23.5)                                 26 (20)
    TRG2                               13 (23.5)                                 17 (13)
    TRG3                               28 (51)                                   75 (58)
    TRG4                               1 (2)                                     12 (9)

In the test cohort the median age was 62 (range, 40--78), in the validation cohort the median age was 64 (range, 35--79). No patients had TRG5. TRG, tumor regression grade according to Mandard *et al* (31); T, tumor; N, node, according to the tumor-node-metastasis (TNM) classification of malignant tumours (UICC, international union against cancer).

###### 

Association between TRG and miR expression in the test cohort (N=55).

         miR expression, median (95% CI)                             
  ------ --------------------------------- ------------------------- -----------
  125b   1.030 (0.558--1.447)              1.708 (0.951--2.026)      0.174
  145    9.854 (5.501--13.846)             17.370 (13.515--25.070)     \<0.001
  21     14.206 (11.529--18.195)           17.463 (16.057--19.450)   0.062
  3      0.128 (0.051--0.235)              0.136 (0.066--0.262)      0.463
  630    0.004 (0.003--0.005)              0.003 (0.002--0.004)      0.104

TRG, tumor regression grade according to Mandard *et al* (31); CI, confidence interval; miR, microRNA.

###### 

Association between TRG and miR expression in the validation cohort (N=130).

         miR expression, median (95% CI)                             
  ------ --------------------------------- ------------------------- -------
  125b   1.338 (1.009--1.729)              1.566 (1.252--1.922)      0.337
  145    18.735 (13.923--22.943)           22.015 (18.164--27.612)   0.085
  21     26.861 (22.906--29.768)           21.107 (19.615--22.829)   0.035
  3      0.109 (0.072--0.391)              0.135 (0.090--0.210)      0.761
  630    0.001 (0.001--0.002)              0.001 (0.001--0.001)      0.333

TRG1+2 vs. TRG3+4. TRG, tumor regression grade according to Mandard *et al* (31); CI, confidence interval; miR, microRNA.

###### 

Univariate Cox\'s regression analysis of the association between clinicopathological characteristics and DFS and OS in the validation cohort (N=130).

                                  DFS    OS                                         
  ------------------------------- ------ ------------ --------- ------ ------------ ---------
  Gender                                 0.50--1.42   0.517            0.64--1.93   0.711
    Female                        1                             1                   
    Male                          0.84                          1.11                
  Age                                    0.84--2.41   0.187            1.22--3.74   0.008
    \<64                          1                             1                   
    ≥64                           1.42                          2.14                
  T-stage                                0.78--2.92   0.220            0.47--2.09   0.973
    T3                            1                             1                   
    T4                            1.51                          0.98                
  N-stage                                0.44--2.16   0.954            0.42--2.04   0.837
    N0                            1                             1                   
    N+                            0.98                          0.92                
  Distance from anal verge (cm)          0.42--2.65   0.913            0.54--3.50   0.497
    ≤5                            1                             1                   
    \>5                           1.05                          1.38                
  TRG                                    0.28--0.94   0.032            0.46--1.44   0.473
    TRG1-2                        0.52                          0.81                
    TRG3-4                        1                             1                   
  Resection status                       1.81--7.19   \<0.001          1.78--7.59   \<0.001
    R0                            1                             1                   
    Not R0                        3.61                          3.68                
  miR-125b expression                    1.14--3.34   0.015            0.74--2.15   0.404
    Above median                  1                             1                   
    Below median                  1.95                          1.26                
  miR-145 expression                     1.04--3.03   0.035            0.81--2.37   0.237
    Above median                  1                             1                   
    Below median                  1.78                          1.38                
  miR-21 expression                      0.48--1.36   0.418            0.43--1.25   0.255
    Above median                  1                             1                   
    Below median                  0.81                          0.73                
  miR-31 expression                      0.75--2.12   0.389            0.74--2.15   0.402
    Above median                  1                             1                   
    Below median                  1.26                          1.26                
  miR-630 expression                     0.68--1.96   0.602            0.79--2.32   0.269
    Above median                  1                             1                   
    Below median                  1.15                          1.35                

DFS, disease-free survival; OS, overall survival; HR, hazard ratio; TRG, tumor regression grade according to Mandard *et al* (31); CI, confidence interval; miR, microRNA; T, tumor; N, node.

###### 

Multivariate Cox\'s regression analysis of the association between clinicopathological characteristics and disease-free survival in the validation cohort (N=130).

                        Multivariate analysis including miR-125b   Multivariate analysis including miR-145                               
  --------------------- ------------------------------------------ ----------------------------------------- ------- ------ ------------ -------
  TRG                                                              0.36--1.28                                0.232          0.34--1.20   0.168
    TRG1-2              0.68                                                                                         0.64                
    TRG3-4              1                                                                                            1                   
  Resection status                                                 1.54--6.47                                0.002          1.49--6.22   0.002
    R0                  1                                                                                            1                   
    Not R0              3.15                                                                                         3.04                
  miR-125b expression                                              1.08--3.20                                0.026                       
    Above median        1                                                                                                                
    Below median        1.86                                                                                                             
  miR-145 expression                                                                                                        0.99--2.91   0.053
    Above median                                                                                                     1                   
    Below median                                                                                                     1.70                

HR, hazard ratio; TRG, tumor regression grade according to Mandard *et al* (31); CI, confidence interval; miR, microRNA.
